Affiliated Cancer Hospital & Institute Of Guangzhou Medical University

This study is testing whether a new two-in-one immunotherapy drug called QL1706, when given with standard chemotherapy before surgery, can help shrink tumors in women with locally advanced cervical cancer. The goal is to see if this approach leads to better surgical outcomes and …

This study is testing a new three-part treatment for ovarian cancer that has returned after initial therapy. It combines a novel immunotherapy drug (QL1706) with standard chemotherapy and a targeted anti-cancer pill (anlotinib). The goal is to see if this combination can better c…